88 results about "Hepatoma cell" patented technology

The invention relates to the field of natural products, in particular to a dimer compound of guaiane type sesquiterpenes and uric acid as well as an extraction and separation method and application of the dimer compound. According to the invention, a new dimer compound of guaiane type sesquiterpene and uric acid is extracted and separated from carpesium abrotanoides in Guizhou, and it is found that the dimer compound has relatively strong anti-tumor activity. The compound has strong inhibitory activity on breast cancer, prostate cancer, nasopharynx cancer, liver cancer, lung cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, skin cancer, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer, and provides an optional scheme for broad-spectrum anti-cancer drugs. Moreover, in human prostate cancer cells PC3, human cervical cancer cells Hela, human liver cancer cells HepG2 and human glioma cells U87 which are resistant to paclitaxel, the compound also shows strong anti-cancer activity, which indicates that the compound has the potential of treating patients resistant to paclitaxel.

The embodiment of the invention discloses a heavy chain variable region and a light chain variable region of an anti-GPC3 monoclonal antibody and application of the heavy chain variable region and the light chain variable region. The high-affinity anti-GPC3 sequence is obtained through screening, the binding specificity of the high-affinity anti-GPC3 sequence and the GPC3 antigen is high, and dissociation is slow. The sequence is used as an extracellular targeting domain to construct GPC3-CAR, after macrophages are transduced through lentivirus, CAR-M can specifically recognize GPC3 positive target cells, activate intracellular signal channels and remarkably improve in-vitro phagocytosis and killing activity, the hepatoma cell lysis effect is better, and technical support is provided for anti-hepatoma application.

The invention discloses application of sodium cantharidinate in preparation of a medicine for promoting CD3 + T cell proliferation, sodium cantharidinate acts on CD3 + T cells, proliferation of the CD3 + T cells can be promoted, human immunity can be effectively improved, and human lung cancer cells H460, human lung cancer cells A549 and human liver cancer cells HepG2 can be effectively killed.

The application relates to a synthesis method of red luminescent carbon dots with a targeting diagnosis and treatment potential of hepatocellular carcinoma, which comprises the following steps: 1) adding 5-fluorouracil and indocyanine green into deionized water, uniformly mixing, and forming a uniform mixed solution; 2) heating the mixed solution obtained in the step 1) at 160-200 DEG C for 5-9 h, and cooling to room temperature; 3) filtering and dialyzing the solution obtained in the step 2), and obtaining a pure 5-FICD solution; and 4) freeze-drying the solution obtained in the step 3), and obtaining the product. The method takes anticancer drug 5-fluorouracil and photosensitizer indocyanine green as precursors, synthesizes a low-toxicity red light carbon dot through a simple hydrothermal method, improves the shortcoming that a chemotherapy drug has a large side effect, and realizes the targeted killing of hepatocellular carcinoma cells.

This invention belongs to the field of biotechnology and pharmaceutical technology, and discloses an ACLY-targeting PROTAC chimera with anti-MASH activity using a glycol chain as the linking chain. Its general structural formula is Formula 1: R is -(CH2-O-CH2). n -, n is 2-6. The PROTAC compound synthesized in this invention is a novel compound. In a high-fat model established using L02 and HepG2 cells, the synthesized PROTAC compound exhibits activity in reducing TG content. Compared with the warhead, the synthesized PROTAC compound shows low toxicity activity in human hepatocellular carcinoma cells HepG2, normal human hepatocytes L02, and human umbilical vein endothelial cells HUVEC, making it a novel, low-toxicity, and highly effective drug for treating non-alcoholic steatohepatitis (NAH). This invention expands the application areas of PROTAC technology while developing a highly effective treatment for NHA.

The application belongs to the technical field of biology and medicine, and discloses a PROTAC compound with a carbon chain as a connecting chain, which is developed based on a PROTAC technology, and a structural general formula of the PROTAC compound is formula 1: wherein R is -(CH2) n -, and n is 3-8. The synthesized PROTAC compound is a new compound, has a TG content reducing activity in a high-fat model established by L02 and HepG2, and has a low-toxicity activity in human hepatoma cells HepG2, human normal liver cells L02 and human umbilical vein endothelial cells HUVEC compared with a warhead. The synthesized PROTAC compound is a new type of anti-non-alcoholic fatty liver disease drug with low toxicity and high efficiency. The application of the PROTAC technology is widened while developing an efficient treatment of anti-non-alcoholic fatty liver disease.

The invention relates to the technical field of medicines, in particular to an enantiomer-atesane type diterpenoid compound as well as a preparation method and an application of the enantiomer-atesane type diterpenoid compound. The enantiomer-atesane diterpenoid compound disclosed by the invention is derived from plants, has anti-tumor activity, has cytotoxicity to human leukemia cells, human liver cancer cells and human cervical cancer cells, and is relatively good in inhibitory activity. Wherein the compound 3 has the best effect, the IC50 values of the compound 3 to three human tumor cells are 7.5 + / -1.2 micromole per liter, 9.8 + / -1.0 micromole per liter and 10.1 + / -0.9 micromole per liter respectively, and the activity of the compound 3 is equivalent to that of a positive control drug mitomycin. Particularly, the compound 3 also has good cytotoxicity to drug-resistant liver cancer cells (Huh7-LR cells), and the IC50 value of the compound 3 is 9.6 + / -1.1 micromole per liter. The compound 3 shows huge potential as a lead compound by virtue of the novel chemical structure and potent cytotoxicity shown in various cell lines.

The application belongs to the technical field of biological medicine, and particularly relates to a galactosamine-doxetaxel conjugate as well as a preparation method and application thereof. First, doxetaxel and 3,3'-diseleno-dipropionic acid are used as raw materials, and after heating reaction, 3,3'-diseleno-dipropionic acid doxetaxel is obtained. Then, the obtained 3,3'-diseleno-dipropionic acid doxetaxel and galactosamine are used as raw materials, and after heating reaction, galactosamine-3,3'-diseleno-dipropionic acid doxetaxel conjugate is obtained through column chromatography separation and purification. The obtained conjugate can be specifically recognized by endogenous lectin receptors (such as asialoglycoprotein receptor ASGPR) which are highly expressed on the surface of hepatoma cells, so as to be taken up by hepatoma cells through a receptor-mediated pathway, and has application prospect in the direction of hepatoma targeted treatment.

The invention belongs to the field of biological medicine, and particularly relates to siRNA for inhibiting INHBE gene expression and a conjugate and application thereof. According to the present invention, the corresponding siRNA is designed according to the INHBE gene, and the siRNA is delivered to the liver by coupling GalNAc so as to interfere the INHBE mRNA at the liver position, such that the expression of the INHBE protein can be effectively reduced, the healthy fat storage can be promoted, and the obesity treatment effect can be further achieved. The siRNA and the siRNA conjugate provided by the invention can be used for remarkably inhibiting proliferation of human liver cancer cells Hep-G2, and have an effect on inhibiting mouse liver INHBE mRNA, so that the siRNA and the siRNA conjugate provided by the invention have a good prospect in application of obesity.

This invention discloses a method for preparing fucoidan from *Sargassum hemifolia* and its application in the preparation of anti-hepatocellular carcinoma drugs. Experimental results show that *Sargassum hemifolia* fucoidan Fb has a strong inhibitory effect on HepG2 hepatocellular carcinoma cells, significantly stronger than the inhibitory effects of *Sargassum henryi* polysaccharide Fh and *Sargassum fusiforme* polysaccharide SFPS on HepG2 hepatocellular carcinoma cells. After treatment of HepG2 hepatocellular carcinoma cells with *Sargassum hemifolia* fucoidan DF1 and DF2, apoptosis is ultimately induced through the interaction and cooperation of exogenous (death receptor pathway) and endogenous (mitochondrial pathway). *Sargassum hemifolia* fucoidan possesses strong antitumor activity and therefore can be used to prepare anti-hepatocellular carcinoma drugs.

This invention discloses a nanoparticle-based drug delivery system, MPL@ICC, its synthesis method, and its applications. The MPL@ICC system consists of hollow, porous nano-MnO2, a hydrophilic targeting complex on its surface, and an acid-responsive drug, INH-CA, and a photosensitizer loaded internally. It possesses both targeted transport and controlled release capabilities against human hepatocellular carcinoma cells (HepG2), allowing it to accumulate within these cells and achieve photodynamic therapy (PDT) and free radical-induced immune killing within the tumor. Simultaneously, it directly kills tumor cells and transforms them from non-immunogenic to immunogenic, mediating an anti-tumor immune response and achieving immunogenic cell death (ICD). This overcomes the shortcomings of ICD-induced cancer treatment strategies, which often fail to produce strong and durable therapeutic effects, and does not induce normal cell apoptosis, thus possessing controllability, effectiveness, and safety.

This invention discloses a mixed hepatocyte terahertz quantitative detection system, electronic device, and medium, comprising: a spectral preprocessing module for acquiring a mixed hepatocyte time-domain spectrum and converting it into a mixed hepatocyte terahertz frequency-domain spectrum using a fast Fourier transform; calculating the refractive index and absorption coefficient to obtain frequency-domain signals of the refractive index and absorption coefficient, and processing them using Gram angle sum field and Gram angle difference field to obtain Gram angle sum field map and Gram angle difference field map; an image feature extraction module for extracting gradient features from the Gram angle sum field map and Gram angle difference field map using gradient histograms; extracting grayscale features from the Gram angle sum field map and Gram angle difference field map using grayscale histograms; fusing the gradient features and grayscale features to obtain image features; and a hepatocyte cancer cell content quantitative detection module for inputting the image features into a pre-trained hepatocyte cancer cell content quantitative detection model to obtain the proportion of hepatocyte cancer cells.

The application belongs to the technical field of molecular biology and drug screening, and provides a method for screening phenylhydrazine sulfate based on a key binding amino acid site of SOCS5-CP and application thereof, which comprises the following steps: key amino acid sites of SOCS5-CP binding are screened through alanine virtual point mutation, and a binding pocket is determined; a ligand molecule is used to perform virtual screening by taking the binding pocket as a docking area, and a compound with the best binding energy is obtained; the obtained drug is screened through AMDET; the selected compound is used for subsequent in-vitro cell experiments, and further screening is performed; the application uses the method of molecular docking and virtual screening in combination with in-vitro experiments for screening, and finds that phenylhydrazine sulfate can be stably combined at the key amino acid sites of SOCS5-CP, in-vitro experiments show that phenylhydrazine sulfate can effectively inhibit the binding of SOCS5-CP, and further down-regulate the protein expression level of HIF1a in hepatoma cells, and also has a significant inhibitory effect on the invasion and migration ability of primary hepatocellular carcinoma.

This invention provides seven guaiacol-type sesquiterpene dimers of structural formula (I), artemisinin dimers A-G (compounds 1-7), their preparation methods, pharmaceutical compositions thereof, and their applications, belonging to the field of pharmaceutical technology. These compounds exhibit inhibitory activity against human liver cancer cell lines HepG2, Huh7, and SK-Hep-1, and can be combined with pharmaceutically acceptable carriers to form pharmaceutical compositions, enabling the preparation of anti-liver cancer drugs.

The invention provides a DNA frame confinement probe, a preparation method thereof and application of the DNA frame confinement probe in drawing cell membrane interface small molecule mercaptan fluctuation. The probe comprises a framework and functional components, the functional components comprise a small molecule thiol response unit, a cell membrane targeting unit and a fluorescent unit, and the functional components are connected to the framework. The framework is of a regular tetrahedral structure and is formed by an S1-8th chain, an S2-overhang chain, an S3-overhang chain and an S4 chain through base complementary pairing and self-assembly. The small molecule thiol response unit is a fluorescent probe CyS2 and is coupled with the S1-8th chain through a copper-free click chemical reaction. The cell membrane targeting unit is formed by combining a Chol-Capture oligonucleotide chain with a complementary sequence at the tail end of a S2-overhang chain and a complementary sequence at the tail end of a S3-overhang chain. And the fluorescence unit is marked at the 3'end of the S2-overhang chain by an Alexa Fluor 488 fluorescence molecule. The DFP-C provided by the invention can specifically target a cell membrane interface, and space-time dynamic imaging of cell membrane interface small molecular biological thiol flux is realized in various liver cancer cells at subcellular spatial resolution.

The application discloses an alpha-linolenic acid and metal iridium coupling compound, a preparation method and application thereof, and relates to the field of medicine, in particular to an alpha-linolenic acid and metal iridium coupling compound, which has good antitumor activity on human cervical cancer cells, human hepatoma cells and mouse breast cancer cells. The preparation method is simple and easy to operate, and the product has good antitumor activity.

This invention belongs to the field of liver cancer chips and drug evaluation, specifically disclosing a liver cancer chip based on a microporous array, its preparation method, and its applications. The liver cancer chip of this invention involves the overall design and modeling of a resin chip mold, including a concentration gradient generation module and a microporous array cell culture module. The resin mold is then printed using surface projection micro-stereolithography, and finally bonded using a template replication method and plasma treatment to obtain a complete liver cancer chip. The liver cancer chip prepared by this invention can be used for in vitro drug evaluation. Its concentration gradient generation module can stably generate multiple drug concentrations, while its downstream microporous array cell culture module can efficiently generate uniformly sized and highly active liver cancer cell spheroids, which is expected to be promoted and applied in personalized, high-throughput drug evaluation.

The invention discloses a preparation method and application of a urea triazole derivative which is simple and easy to operate, cheap and easily available in raw materials, high in reaction efficiency and good in inhibition effect on human liver cancer cells Huh-7, and belongs to the technical field of medicine synthesis. According to the key points of the technical scheme, the urea triazole derivative molecule has a structure, or R1 is hydrogen atom, fluorine, chlorine, bromine, iodine, nitryl, alkyl (such as methyl, ethyl or alkynyl) or alkoxy (such as methoxyl) and various substituent groups, R2 is phenyl derivative or benzyl derivative, and X is oxygen atom or sulfur atom. The invention designs and synthesizes a urea triazole derivative with a novel structure, and the compound has a good inhibition effect on human liver cancer cells Huh-7.

The application discloses a milk-derived small molecular peptide, which has an amino acid sequence of Phe-Gly-Gly-Leu-Met (FGGLM) and a molecular weight of 523.64 Da. The small molecular peptide has the characteristics of inhibiting the activity of pancrelipases (PL) and reducing the accumulation of triglyceride (TG) content in oleic acid-induced human hepatoma (Hepg2) cells. The small molecular peptide can be applied to the preparation of preparations for treating or assisting in treating hyperlipidemia and obese people, and has the characteristics of simple preparation, suitability for industrial production and market promotion and application.

The invention relates to the field of bioengineering, in particular to a function-synergetic bionic gene editing carrier system as well as a preparation method and application thereof. The invention provides a gene editing expression box. The gene editing expression box comprises a cancer cell specific promoter, a CXCL9 gene, an sgBAG3 gene and an sgHSP70 gene. A bionic lipid carrier with protein adsorption resistance, cancer cell targeting and membrane fusion delivery is constructed, and an integrated gene editing CRISPR system capable of highly expressing CXCL9 protein factors in cancer cells and double editing tumor cell BAG3 and HSP70 genes is entrapped, so that a multifunctional synergetic bionic gene editing carrier system is constructed; according to the invention, in-vivo delivery stability of the CRISPR system, cancer cell targeting accuracy and intracellular release high efficiency are realized, liver cancer cell gene editing efficiency is improved, a T cell killing enhancement effect tumor immune microenvironment is constructed, and effective cancer resistance of the CRISPR system in a tumor environment is realized.

The invention provides arteannuin A1A4 (artemannuins A1A4, 14), arteannuin B1B4 (artemannuins B1B4, 57), arteannuin C1C2 (artemannuins C1, C2, 8 and 9) and arteannuin DH (artemannuins DH, 1014), a pharmaceutical composition of the arteannuin A1A4, the arteannuin B1B4, the arteannuin C1C2, the arteannuins C1, C2, 8 and 9) and the arteannuin DH, and a preparation method and application of the arteannuin A1A4, the arteannuin B1B4, the arteannuin C1C2, the arteannuin C1C2, the arteannuin DH and the arteannuin DH, and belongs to the technical field of medicine. The 14 cadinane type sesquiterpene dimers shown in the structural formula (I) have an inhibiting effect on human hepatoma cell lines HepG2, Huh7 and SK-Hep-1, can form a pharmaceutical composition with a pharmaceutically acceptable carrier or excipient, and can be used for preparing anti-hepatoma drugs.

The invention provides synthesis and application of a tetravalent platinum prodrug with a mitochondrial GLS / mt-DNA dual-targeting function. According to the invention, oxaliplatin-resistant liver cancer cell mitochondria is taken as a target spot, tetravalent platinum is taken as a skeleton template, a double-drug multifunctional tetravalent platinum prodrug (LND-Pt-TPP) capable of co-targeting mitochondria GLS1 and mt-DNA is synthesized, and liver cancer treatment sensitivity of oxaliplatin is restored by intervening drug-resistant cell glutamine metabolism and avoiding DNA damage repair. The pharmaceutical composition is used for treating oxaliplatin-resistant liver cancer. The invention further studies the action mechanism that the tetravalent platinum prodrug (LND-Pt-TPP) with the mitochondrial GLS / mt-DNA dual-targeting function intervenes in GLS1 mediated glutamine metabolism to increase the formation of an mt-DNA-Pt compound, and has very important clinical application value.

The application belongs to the technical field of medicine, and relates to extraction and separation of a guaiane sesquiterpene glycoside compound guaiane sesquiterpene glycoside II from rhizome of rabdosia japonica by using macroporous resin, normal-phase silica gel, reverse-phase silica gel and dextran gel column chromatography and recrystallization and the like. 21 H 36 O8, in-vitro anti-tumor activity research shows that the compound has good anti-tumor activity, including obvious inhibition on human gastric cancer cells BGC-823, human hepatoma cells HepG-2 and human lung cancer cells A549. The application can provide a source of pharmacodynamic material basis for development of anti-tumor drugs, and has development and application prospects.

This invention relates to the preparation of 10-trifluoromethoxycamptothecin compounds and their use in antitumor drugs. The structural formula of these compounds is shown below. In vitro cytotoxicity screening results show that 10-trifluoromethoxycamptothecin compounds possess broad-spectrum antitumor activity, exhibiting strong inhibitory activity against human hepatocellular carcinoma cells (HepG2), human non-small cell lung cancer cells (A549), human colon cancer cells (SW480), human cholangiocarcinoma cells (QBC939), human breast cancer cells (MCF-7), human pancreatic cancer cells (PANC-1), and human pancreatic cancer cells (BxPC-3). Compounds 10-trifluoromethoxycamptothecin I and 7-ethyl-10-trifluoromethoxycamptothecin II showed strong inhibitory effects against all seven tested tumor cell lines, with IC50 values ​​exceeding 100%. 50 The concentrations were 0.913–0.0661 μM and 4.932–0.0578 μM, respectively, both significantly superior to the control drug topotecan. Among them, compounds I and II exhibited the strongest inhibitory activity against the BxPC-3 cell line, with IC50 values ​​of [missing value]. 50 The values ​​were 0.0661±0.0065μM and 0.0578±0.0043μM, respectively. Therefore, 10-trifluoromethoxycamptothecin compounds hold promise for development into a novel antitumor drug.

The invention relates to the technical field of biological medicines, and particularly discloses a cancer suppression small interfering RNA (Ribonucleic Acid) capable of simultaneously targeting cancer genes PTTG1 and STMN1 and application of the cancer suppression small interfering RNA, and the technical key points are as follows: the positive-sense strand sequence of the small interfering RNA is GGGAGAUCUCAAGUUUCAATT, and the antisense strand sequence of the small interfering RNA is UUGAAACUUGAGAUCUCCCTT. The small interfering RNA provided by the invention can specifically silence the expression of PTTG1 and STMN1 at the same time. Compared with siRNA (such as siRNA for ASCC3 or TRAPPC4) targeting a single gene in the prior art, the siRNA provided by the invention has the advantages that synergistic inhibition on tumor proliferation and metastasis pathways is realized through double-targeting design, and the inhibition effect on tumor cell growth is more remarkable; compared with a method of physically mixing two single siRNAs, the method provided by the invention has higher cell apoptosis induction efficiency and better in-vivo tumor inhibition effect; the small interfering RNA is effective in various liver cancer cells, has a lasting effect in an animal model, and provides a core molecular entity for developing novel antitumor drugs.

The invention belongs to the technical field of polypeptide drugs, and particularly relates to a series of polypeptides with an anti-cancer effect and application thereof. According to the invention, Rink amide MBHA amino resin is used as a solid phase carrier, modification is carried out according to an amino acid sequence of a template polypeptide Hymenochirin-1Pa (H-0): Ac-LKLSPKTKDTLKKVLKGAIKGAIAIASAMA-NH2, and on the basis of retaining key amino acid residues, original amino acids are replaced by R8 and S5 at the positions of i and i + 7 amino acids, so that the target stapling peptide is obtained. Compared with a template polypeptide H-0, the obtained stapled peptide has the advantage that the anti-tumor activity on human liver cancer cells Huh7, human non-small cell lung cancer cells A549, glioma cells U87 and colon cancer cells T84 can be obviously improved.

This invention belongs to the field of biomedical technology, specifically relating to a Pt 2+ - Carbon dot@protoporphyrin sonodynamic drug delivery system, its preparation method and application, by loading Pt onto the surface of carbon dots 2+ Modification layer, to obtain Pt 2+ After carbon dots are formed, protoporphyrin is loaded onto them to obtain a carbon dot core with Pt loaded on the carbon dot surface. 2+ Modification layer, in Pt 2+ A sonodynamic drug delivery system with a protoporphyrin-modified layer loaded on the outside of the modified layer can be used in anti-tumor drugs to screen liver cancer cells and normal cells. It has good biocompatibility and significant in vivo sonodynamic anti-tumor effects. It can promote the generation of reactive oxygen species, target and remain in the subcutaneous tumor site in vivo for a long time, increase the mortality rate of cancer cells, and inhibit tumor growth. In a 3D constructed in vitro hepatocellular tumor microenvironment model, this drug delivery system still has superior sonodynamic therapeutic effects.

The invention discloses an analysis and identification method of N-acylamino acid and application of the analysis and identification method. According to the method, a one-pot method is adopted, amino acid and fatty acid are synthesized into a target object under the action of a coupling reagent, a derivatization reagent N, N-diisopropylethylenediamine (DIAAA) is directly added for in-situ chemical derivatization without separation, and then liquid chromatography-mass spectrometry (LC-MS) analysis is carried out. And carrying out structure identification according to the DIAAA characteristic fragment, the amino acid residue fragment and the acyl fragment. The method can be extensively used for systematic identification and quantitative analysis of complex biological samples, and is especially suitable for N-oleoyl amino acid. Experiments prove that N-oleoyl tyrosine, proline, leucine and tryptophan have remarkable inhibitory activity on hepatoma cells HepG2, which indicates that the N-oleoyl tyrosine, proline, leucine and tryptophan have application potential in preparation of anti-hepatoma drugs. According to the method, efficient and accurate analysis of the N-acylamino acid is realized.

The invention discloses an NK cell killing resistant cell strain as well as a construction method and application thereof. The NK cell killing resistant cell strain is named as a human liver cancer cell HepG2-NK-R Homo sapiens, and is preserved in the China Center for Type Culture Collection on November 05, 2025, and the preservation number is CCTCC (China Center for Type Culture Collection) NO: C2025298. The human hepatoma cell line HepG2 is exposed to NK cells for a long time for co-culture to obtain the human hepatoma cell line HepG2. The cell strain has a stable biological phenotype through in-vitro simulation of NK cell mediated long-term immune editing. Compared with parental cells, the cell line shows remarkably enhanced malignant biological behaviors, can be used for researching occurrence, development and metastasis of liver cancer or preparing a tumor cell model or a tumor animal model, is greatly improved in tumor forming ability, in-vivo proliferation speed and metastasis speed, can remarkably shorten an experimental period, and can highly restore invasion characteristics of tumors after evolution.